

Rune Nilsson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1870531/publications.pdf>

Version: 2024-02-01

33
papers

434
citations

840776

11
h-index

752698

20
g-index

33
all docs

33
docs citations

33
times ranked

351
citing authors

#	ARTICLE	IF	CITATIONS
1	The interaction between different domains of staphylococcal protein a and human polyclonal IgG, IgA, IgM and F(ab') ₂ : Separation of affinity from specificity. <i>Molecular Immunology</i> , 1993, 30, 1279-1285.	2.2	109
2	A Novel Platform for Radioimmunotherapy: Extracorporeal Depletion of Biotinylated and ⁹⁰ Y-Labeled Rituximab in Patients with Refractory B-Cell Lymphoma. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2005, 20, 457-466.	1.0	33
3	Fractionation of rat IgG subclasses and screening for IgG Fc-binding to bacteria. <i>Molecular Immunology</i> , 1982, 19, 119-126.	2.2	31
4	A novel approach to monoclonal antibody separation using high performance liquid affinity chromatography (HPLAC) with SelectiSpher-10 protein G. <i>Journal of Immunological Methods</i> , 1988, 114, 175-180.	1.4	25
5	Trifunctional Conjugation Reagents. Reagents That Contain a Biotin and a Radiometal Chelation Moiety for Application to Extracorporeal Affinity Adsorption of Radiolabeled Antibodies. <i>Bioconjugate Chemistry</i> , 2002, 13, 1079-1092.	3.6	19
6	Quantitative analysis of rat Ig (sub) classes binding to cell surface antigens. <i>Journal of Immunological Methods</i> , 1982, 55, 179-191.	1.4	18
7	Antigen-independent binding of rat immunoglobulins in a radioimmunoassay. Solutions to an unusual background problem. <i>Journal of Immunological Methods</i> , 1984, 66, 17-25.	1.4	18
8	Determining Maximal Tolerable Dose of the Monoclonal Antibody BR96 Labeled with ⁹⁰ Y or ¹⁷⁷ Lu in Rats: Establishment of a Syngeneic Tumor Model to Evaluate Means to Improve Radioimmunotherapy. <i>Clinical Cancer Research</i> , 2005, 11, 7104s-7108s.	7.0	13
9	High-dose radioimmunotherapy combined with extracorporeal depletion in a syngeneic rat tumor model. <i>Cancer</i> , 2010, 116, 1043-1052.	4.1	13
10	Use of Monte Carlo simulations with a realistic rat phantom for examining the correlation between hematopoietic system response and red marrow absorbed dose in Brown Norway rats undergoing radionuclide therapy with ¹⁷⁷ Lu- and ⁹⁰ Y-BR96 mAbs. <i>Medical Physics</i> , 2012, 39, 4434-4443.	3.0	13
11	Reduced myelotoxicity with sustained tumor concentration of radioimmunoconjugates in rats after extracorporeal depletion. <i>Journal of Nuclear Medicine</i> , 2007, 48, 269-76.	5.0	12
12	Extracorporeal Immunoabsorption from Whole Blood Based on the Avidin-Biotin Concept: Evaluation of a new method. <i>Acta Oncologica</i> , 1996, 35, 309-312.	1.8	11
13	Improved Tumor Targeting and Decreased Normal Tissue Accumulation through Extracorporeal Affinity Adsorption in a Two-Step Pretargeting Strategy. <i>Clinical Cancer Research</i> , 2007, 13, 5572s-5576s.	7.0	11
14	Blood Pharmacokinetics of Various Monoclonal Antibodies Labeled with a New Trifunctional Chelating Reagent for Simultaneous Conjugation with 1,4,7,10-Tetraazacyclododecane-N,N'-bis(2,2,6,6-tetraacetic Acid) and Biotin before Radiolabeling. <i>Clinical Cancer Research</i> , 2005, 11, 7171s-7177s.	7.0	10
15	Different protein A immunosorbents may have different binding specificity for rat immunoglobulins. <i>Journal of Immunological Methods</i> , 1983, 62, 241-245.	1.4	9
16	Repeated Radioimmunotherapy with ¹⁷⁷ Lu-DOTA-BR96 in a Syngeneic Rat Colon Carcinoma Model. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2012, 27, 134-140.	1.0	9
17	Successful radioimmunotherapy of established syngeneic rat colon carcinoma with ²¹¹ At-mAb. <i>EJNMMI Research</i> , 2013, 3, 23.	2.5	9
18	A general extracorporeal immunoabsorption method to increase tumor-to-tissue ratio. <i>Cancer</i> , 1994, 73, 1033-1037.	4.1	8

#	ARTICLE	IF	CITATIONS
19	The Intratumoral Distribution of Radiolabeled ¹⁷⁷ Lu-BR96 Monoclonal Antibodies Changes in Relation to Tumor Histology over Time in a Syngeneic Rat Colon Carcinoma Model. <i>Journal of Nuclear Medicine</i> , 2013, 54, 1404-1410.	5.0	8
20	Improving Radioimmunotargeting of Tumors: Variation in the Amount of L6 Mab Administered, Combined with an Immunoabsorption System (Ecia). <i>Acta Oncol³gica</i> , 1993, 32, 853-859.	1.8	7
21	Biocompatibility of a Novel Avidin-Agarose Adsorbent for Extracorporeal Removal of Redundant Radiopharmaceutical From the Blood. <i>Artificial Organs</i> , 2007, 31, 208-214.	1.9	7
22	Treatment with Unlabeled mAb BR96 After Radioimmunotherapy with ¹⁷⁷ Lu-DOTA-BR96 in a Syngeneic Rat Colon Carcinoma Model. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2012, 27, 175-182.	1.0	7
23	Toxicityâ€reducing potential of extracorporeal affinity adsorption treatment in combination with the auristatinâ€conjugated monoclonal antibody BR96 in a syngeneic rat tumor model. <i>Cancer</i> , 2010, 116, 1033-1042.	4.1	6
24	Sequential Radioimmunotherapy with ¹⁷⁷ Lu- and ²¹¹ At-Labeled Monoclonal Antibody BR96 in a Syngeneic Rat Colon Carcinoma Model. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2014, 29, 238-246.	1.0	6
25	A Nonsurgical Technique for Blood Access in Extracorporeal Affinity Adsorption of Antibodies in Rats. <i>Artificial Organs</i> , 2007, 31, 312-316.	1.9	4
26	Extracorporeal Adsorption Therapy: A Method to Improve Targeted Radiation Delivered by Radiometal-Labeled Monoclonal Antibodies. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2008, 23, 181-191.	1.0	4
27	Quantitation of protein A in human plasma is possible after heat inactivation of the samples. <i>Journal of Immunological Methods</i> , 1990, 135, 77-80.	1.4	3
28	Change in Cell Death Markers During ¹⁷⁷ Lu-mAb Radioimmunotherapy-Induced Rejection of Syngeneic Rat Colon Carcinoma. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2014, 29, 143-152.	1.0	3
29	Different toxicity profiles for drug- versus radionuclide-conjugated BR96 monoclonal antibodies in a syngeneic rat colon carcinoma model. <i>Acta Oncol³gica</i> , 2011, 50, 711-718.	1.8	2
30	Pattern of antigen expression in metastases after radioimmunotherapy of a syngeneic rat colon carcinoma utilizing the BR96 antibody. <i>Experimental Hematology and Oncology</i> , 2012, 1, 34.	5.0	2
31	Role of CD8-positive cells in radioimmunotherapy utilizing ¹⁷⁷ Lu-mAbs in an immunocompetent rat colon carcinoma model. <i>EJNMMI Research</i> , 2015, 5, 3.	2.5	2
32	Comparison of the Mitogenic Activities of Streptococcal Protein-G and Staphylococcal Protein-A on Human Mononuclear Cells. <i>Immunological Investigations</i> , 1989, 18, 919-930.	2.0	1
33	Evaluation of immune cell markers in tumor tissue treated with radioimmunotherapy in an immunocompetent rat colon carcinoma model. <i>EJNMMI Research</i> , 2015, 5, 47.	2.5	1